Boston, MA -- (SBWIRE) -- 03/13/2014 -- We anticipate further restrictions to medicine prices in 2014 under the Medicines Prices Act, which will subdue the outlook for both patented and generic drugmakers in the country. This comes despite expectations for a return to positive economic growth in 2014, as the Dutch government will persist with austerity measures to comply with EU budgetary requirements. While our short-term outlook for healthcare expenditure is steady, spending growth has levelled off since 2011, with the proportion of GDP allocated to healthcare projected to gradually shrink over our forecast period to 2023.
Headline Expenditure Projections
- Pharmaceuticals: EUR6.87bn (US$9.07bn) in 2013 to EUR6.74bn (US$8.56bn) in 2014; -1.9% in local currency terms and -5.6% in US dollar terms.
- Healthcare: EUR76.07bn (US$100.41bn) in 2013 to EUR77.56bn (US$98.50bn) in 2013; 2.0% in local currency terms and -1.9% in US dollar terms.
View Full Report Details and Table of Contents
The Netherlands continues to rank in the lower half of BMI's Pharmaceutical Risk/Reward Ratings (RRRs) for the 14 key Western European markets, and remains 10th in our ratings for Q214. The country fell from eighth in Q413. At an unchanged 66, its overall RRR score remains only slightly below the regional average of 67. This was the result of the rise of Finland and the incorporation of Denmark in our ratings system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.
Key Trends And Developments
- In December 2013, the European Commission (EC) imposed fines of EUR10.80bn (US$14.62bn) and EUR5.49bn (US$7.44bn) on the Dutch subsidiaries of Johnson & Johnson and Novartis respectively. According to the EC, in July 2005 the subsidiaries concluded an anticompetitive agreement to delay the market entry of cheaper generic versions of the analgesic fentanyl in the Netherlands. This was in breach of EU antitrust rules.
- In November 2013, Dutch chemicals and nutrition company DSM agreed to spin off its pharmaceutical manufacturing business, DSM Pharmaceutical Products, as a US$2.6bn joint venture with US-based private equity firm JLL Partners. DSM Pharmaceutical will be merged with Canada-based specialtypharmaceuticals manufacturer Patheon, which is controlled by JJL. The new entity, which will be 51% owned by JLL and 49% by DSM, is estimated to have annual sales of about US$2bn. The still-unnamed company will develop and manufacture active pharmaceutical ingredients, finished dosages and drug products.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
- Japan Pharmaceuticals & Healthcare Report Q2 2014
- Australia Pharmaceuticals & Healthcare Report Q2 2014
- Oman Pharmaceuticals & Healthcare Report Q2 2014
- Jordan Pharmaceuticals & Healthcare Report Q2 2014
- Algeria Pharmaceuticals & Healthcare Report Q2 2014